PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsNetarsudil
Rhopressa, Rhokiinsa(netarsudil)
Rhokiinsa, Rhopressa, Rocklatan, Roclanda (netarsudil) is a small molecule pharmaceutical. Netarsudil was first approved as Rhopressa on 2017-12-18. It is used to treat ocular hypertension and open-angle glaucoma in the USA. It has been approved in Europe to treat ocular hypertension and open-angle glaucoma. It is known to target rho-associated protein kinase 1 and rho-associated protein kinase 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
eye diseasesD005128
Trade Name
FDA
EMA
Rhopressa
Combinations
Rocklatan
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Netarsudil mesylate
Tradename
Company
Number
Date
Products
RHOPRESSAAlcon ResearchN-208254 RX2017-12-18
1 products, RLD, RS
Latanoprost
+
Netarsudil dimesylate
Tradename
Company
Number
Date
Products
ROCKLATANAlcon ResearchN-208259 RX2019-03-12
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
rhopressaNew Drug Application2025-09-29
rocklatanNew Drug Application2025-03-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
ocular hypertensionEFO_1001069D009798H40.0
open-angle glaucomaEFO_0004190D005902H40.1
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Latanoprost / Netarsudil Dimesylate, Rocklatan, Alcon Labs Inc
94150432034-03-14DP
99313362034-03-14DS, DPU-1524
99934702034-03-14DS, DPU-1524
105889012034-03-14DS, DPU-1524
111855382034-03-14DP
111978532034-03-14DP
83948262030-11-10DS, DPU-1524
101740172030-01-27DS, DPU-1524
106548442030-01-27DS, DPU-1524
110280812030-01-27U-1524
116187482030-01-27U-1524
84503442026-07-11DS, DPU-1524
90965692026-07-11DS, DPU-1524
105329932026-07-11U-1524
108828402026-07-11U-1524
110214562026-07-11U-1524
ATC Codes
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01E: Antiglaucoma preparations and miotics
— S01EE: Prostaglandin analogues, antiglaucoma drugs and miotics
— S01EE51: Latanoprost and netarsudil
— S01EX: Other antiglaucoma preparations in atc
— S01EX05: Netarsudil
HCPCS
No data
Clinical
Clinical Trials
43 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GlaucomaD005901EFO_0000516H40—885526
Ocular hypertensionD009798EFO_1001069H40.0—992222
Open-angle glaucomaD005902EFO_0004190H40.11983122
HypertensionD006973EFO_0000537I10—642113
Low tension glaucomaD057066EFO_1001022H40.12———2—2
HyperemiaD006940EFO_0003822H34.82———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Fuchs' endothelial dystrophyD005642EFO_0003946H18.51233—17
Corneal edemaD015715EFO_1000879H18.20—21—13
Retinal detachmentD012163EFO_0005773H33.2121——2
Proliferative vitreoretinopathyD018630EFO_1001129—121——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hereditary corneal dystrophiesD003317—H18.5—1——12
EdemaD004487—R60.9—1———1
Dissociative disordersD004213—F44.111———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CataractD002386EFO_0001059H26.91———12
Healthy volunteers/patients———2————2
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PseudophakiaD019591——————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNetarsudil
INNnetarsudil
Description
Netarsudil, sold under the brand name Rhopressa among others, is a medication for the treatment of glaucoma. In the United States, in December 2017, the Food and Drug Administration (FDA) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension. The European Medicines Agency approved it in 2019 for the same uses under the brand name Rhokiinsa.
Classification
Small molecule
Drug classvasodilators (undefined group): Rho protein kinase (ROCK) inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(C(=O)OCc2ccc([C@@H](CN)C(=O)Nc3ccc4cnccc4c3)cc2)c(C)c1
Identifiers
PDB—
CAS-ID1254032-66-0
RxCUI—
ChEMBL IDCHEMBL4594250
ChEBI ID—
PubChem CID66599893
DrugBankDB13931
UNII IDW6I5QDT7QI (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
ROCK1
ROCK1
ROCK2
ROCK2
Organism
Homo sapiens
Gene name
ROCK1
Gene synonyms
NCBI Gene ID
6093
Protein name
rho-associated protein kinase 1
Protein synonyms
p160 ROCK-1, p160ROCK, Renal carcinoma antigen NY-REN-35, Rho-associated, coiled-coil-containing protein kinase 1, Rho-associated, coiled-coil-containing protein kinase I, ROCK-I
Uniprot ID
Q59GZ4
Mouse ortholog
Rock1 (19877)
rho-associated protein kinase 1 (Q8C7H0)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 593 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,875 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use